Pyruvate Dehydr..

Pyruvate Dehydrogenase Complex Deficiency (PDHCD) is a mitochondrial disease that leads to lactic acidosis without hypoglycemia.

Pyruvate Dehydrogenase Deficiency.

The exact incidence is unknown, but several hundred cases have been described.

All the components of the pyruvate dehydrogenase complex are encoded by nuclear genes and are synthesized in the cytoplasm before being transported into the mitochondria. Most of these genes are autosomal, but the E1α subunit gene has been mapped to Xp22.3. Hence, most cases of pyruvate dehydrogenase complex deficiency are X-linked with more severe consequences in males than in heterozygous females; the frequency, however, is the same for both genders.

Pyruvate dehydrogenase (PDH) is an enzyme complex consisting of three catalytic subunits, pyruvate dehydrogenase (E1, a tetramer), dihydrolipoamide acyltransferase (E2, a monomer), and dihydrolipoamide dehydrogenase (E3, a dimer), and two cofactors, thiamine pyrophosphate and lipoic acid. A sixth component, previously named X-protein and recently renamed E3-binding protein (E3-BP), has been found to be mutated in a few patients. The enzyme complex converts pyruvate—after it enters the mitochondria—into acetyl-CoA, one of two essential substrates (oxaloacetate being the other) in the production of citrate. PDHCD therefore leads to a limited production of citrate and because citrate is the first substrate in the tricarboxylic acid (citric acid or Krebs) cycle, the cycle is blocked and other metabolic pathways need to be stimulated to produce acetyl-CoA. Nevertheless, the decreased level of energy substrates (ATP) primarily affects the CNS, because brain acetyl-CoA is synthesized almost exclusively from pyruvate. The most common deficiency involves the E1 subunit, a heterotetramer consisting of two alpha and two beta subunits with the defect located on the alpha subunit (E1alpha), which contains several serine phosphorylation sites and seems to be involved in the regulation of the whole complex. Mutations in E2, E3, and E3-BP are less often the cause for PDHCD. The enzyme defect causes more pyruvate to be metabolized to lactate and leads to lactic acidosis.

The combination of an otherwise unexplained lactic acidosis with early-onset neurological disease and structural brain anomalies should always include PDHCD in the differential diagnosis. In addition to pyruvate carboxylase deficiency, defects in the mitochondrial chain of electron transport or in gluconeogenesis should be considered. However, lactic acidosis in the absence of hypoglycemia does not match with a defect in gluconeogenesis, whereas a defect in the mitochondrial respiratory chain would also affect other organ systems, such as muscle, heart, liver, and kidneys. In contrast to a respiratory chain defect, the blood lactate/pyruvate ratio in PDHCD is normal and both lactate and pyruvate decrease after fasting. Specific enzyme assays are available to measure the total PDH activity, as well as that of the individual components of the enzyme complex. However, measured residual enzyme activity does not always correlate with the clinical picture.

The range of clinical expression is wide and has four different ways of presentation: fatal infantile lactic acidosis, psychomotor retardation, progressive ...

Sign in to your MyAccess profile while you are actively authenticated on this site via your institution (you will be able to verify this by looking at the top right corner of the screen - if you see your institution's name, you are authenticated). Once logged in to your MyAccess profile, you will be able to access your institution's subscription for 90 days from any location. You must be logged in while authenticated at least once every 90 days to maintain this remote access.

Ok

## Subscription Options

### AccessAnesthesiology Full Site: One-Year Subscription

Connect to the full suite of AccessAnesthesiology content and resources including procedural videos, interactive self-assessment, real-life cases, 20+ textbooks, and more